A novel therapeutic drug (copper nicotinic acid complex) for non-alcoholic fatty liver
Article first published online: 9 MAR 2007
Volume 27, Issue 4, pages 454–464, May 2007
How to Cite
Salama, R. H. M., Nassar, A. Y. A., Nafady, A. A. M. and Mohamed, H. H. T. (2007), A novel therapeutic drug (copper nicotinic acid complex) for non-alcoholic fatty liver. Liver International, 27: 454–464. doi: 10.1111/j.1478-3231.2007.01460.x
- Issue published online: 9 MAR 2007
- Article first published online: 9 MAR 2007
- Received 19 October 2006accepted 15 January 2007
Vol. 27, Issue 8, 1156, Article first published online: 6 SEP 2007
- animal model;
- copper complex;
- fatty liver;
Background: Fatty liver is the accumulation of fat in liver cells, which leads to disruption of the normal liver structure and function.
Methods: A non-alcoholic fatty liver rat model received copper (Cu) (I)-nicotinate complex [CuCl(HNA)2] for 4 weeks.
Results: Clinical signs and histopathological examinations showed obvious improvements in rats that received Cu complex who were continuously on an (HCFF) diet than those returned to standard diet with Cu complex. The improvement was matched in total lipids in sera and hepatic tissue, with disappearance of fat droplets from liver sections. Furthermore, the gain in body weight and the corresponding decrease in liver weight, decreased liver transaminases and alkaline phosphatase were prominent. The oxidative stress markers such as nitric oxide, lipid peroxides, glutathione and superoxide dismutase were obviously changed to healthy normal levels.
Conclusion: The Cu complex may serve as a novel chemical restoring agent in fatty degenerated liver cells and for renewal of their structure and functions. However, clinical trials are required for more evaluation of the Cu complex in humans.